Constant Systems founded in 1989 operates in the Pharmaceutical and Medical Research sector manufacturing high pressure cell disruption equipment used in the development of lifesaving vaccines and drugs throughout the world.
This thriving organisation is truly an International operation supplying over 100 countries world-wide and has long standing International partners in the USA, China, and Europe including leading Research Universities. University of Oxford https://www.bioch.ox.ac.uk/, University of Cambridge https://www.path.cam.ac.uk/ and Harvard Medical School https://micro.hms.harvard.edu/ Constant Systems business is central to the future development of the Crompton Group who are investing in additional resource and product development to enable this exciting company to maximise its potential.
“At a time when UK exporting is considered to be a challenge, we intend to prove that theory wrong! Crompton are so pleased to have acquired this business who not only have a world leading product but also a fantastic team of people to lead it into a very positive future.”JOHN BRADLEY – CROMPTON GROUP CHAIRMAN
Richard Mallabar will continue in his position as Managing Director with his vast experience and desire to expand, Jonathan Adams will act as Constant Systems Finance Director
Many thanks to Schofield Sweeney and Graham Camm for their efforts in securing the transaction.
Holding ISO 9001:2015, UL 61010-1:2004 and CSA C22.2#61010-1-04:2004 accreditations our dedication to supply and support our client base is second to none. With continued research into client requirements and implementing these into safe and efficient means of cell lysis processes we have progressively grown and maintained a worldwide client base and see ourselves as a front runner for Cell Disruption equipment with over 1,300 pieces of equipment sold around the globe. https://constantsystems.com/